chevron_leftBack
As of 24 April 2025, Lunit Inc. has a market cap of $1.08B USD, ranking #7792 globally and #175 in South Korea. It ranks #749 in the Healthcare sector, and #31 in the Health Information Services industry.
Key Stats
Market Cap
$1.08BUSD
1.55T KRW
Enterprise Value
$1.09BUSD
1.56T KRW
Revenue (TTM)
$37.96MUSD
54.18B KRW
EBITDA (TTM)
-$42.02MUSD
-59.97B KRW
Net Income (TTM)
-$57.74MUSD
-82.42B KRW
EBITDA Margin
-111%
Profit Margin
-152%
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Health Information Services
CEO
Beomseok Brandon Suh
open_in_new
Founded
2013
Website
lunit.io
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.7% | 1.3% | -1.8% | -20% | 37% | -0.9% |
Upcoming Earnings
Earnings Date
Wed, May 14
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
328130
루닛
ISIN: KR7328130000
Shares Out.:
Shares Outstanding:
28.995M1
Shares Float:
21.541M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
53.4K KRW |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Lunit Inc.
Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations. Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.
